Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting

BACKGROUND: Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs. Despite these advantages, data are limited on the real‐world use of desmopressin in the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwagemaker, Anne‐Fleur, Kloosterman, Fabienne R., Coppens, Michiel, Gouw, Samantha C., Boyce, Sara, Bagot, Catherine N., Beckers, Erik A. M., Brons, Paul, Castaman, Giancarlo, Eikenboom, Jeroen, Jackson, Shannon, Kruip, Marieke J. H. A., Leebeek, Frank W. G., Meijer, Karina, Nieuwenhuizen, Laurens, Pabinger, Ingrid, Fijnvandraat, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433315/
https://www.ncbi.nlm.nih.gov/pubmed/36090159
http://dx.doi.org/10.1002/rth2.12777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433315/
https://www.ncbi.nlm.nih.gov/pubmed/36090159
http://dx.doi.org/10.1002/rth2.12777

Ejemplares similares